ArticleCancers2024

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("

Alessandro Cafaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.